Aktie A1C9RN LIGAND PHARMACEUTICALS INCORPORATED
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Ligand Pharmaceuticals Incorporated

Aktien

A1C9RN

US53220K5048

LGND

Markt geschlossen - Nasdaq
Andere Börsenplätze
 22:00:00 28.05.2024 		% 5 Tage % 1. Jan.
85,98 USD -0,49 % Intraday Chart für Ligand Pharmaceuticals Incorporated -1,17 % +20,39 %
13.05. Ligand Pharmaceuticals Insider verkaufte Aktien im Wert von $830,449, laut einer aktuellen SEC Einreichung MT
08.05. Sektor-Update: Aktien des Gesundheitswesens am späten Nachmittag schwächer MT

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Ligand to Participate in Upcoming Investor Conferences
Ligand Pharmaceuticals Insider Sold Shares Worth $830,449, According to a Recent SEC Filing
Sector Update: Health Care Stocks Softer Late Afternoon
Ligand Pharmaceuticals Shares Rise After Q1 Adjusted Earnings, Revenue Beat Views
Ligand: Q1 Earnings Snapshot
Earnings Flash (LGND) LIGAND PHARMACEUTICALS INCORPORATED Posts Q1 Revenue $31M, vs. Street Est of $27.9M
Earnings Flash (LGND) LIGAND PHARMACEUTICALS INCORPORATED Reports Q1 EPS $1.20, vs. Street Est of $0.83
Ligand Reports First Quarter 2024 Financial Results
Ligand Pharmaceuticals Incorporated Reaffirms Earnings Guidance for the Year 2024
Sector Update: Health Care Stocks Stronger in Tuesday Afternoon Trading
Ligand Pharmaceuticals Investing in Agenus to Fund Development of Oncology Drug Candidates
Ligand and Agenus Enter Into $100 Million Royalty Financing Agreement
Ligand to Report First Quarter 2024 Financial Results on May 7, 2024
Ligand Pharmaceuticals Incorporated : Certificate of Incorporation/Bylaws - Form 8-K
Ligand Pharmaceuticals Announces New Topiramate Injection Data Presented at 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference
Ligand Pharmaceuticals Incorporated Announces New Topiram Injection Data Presented At 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference
Ligand Pharmaceuticals Announces Launch of Pelthos Therapeutics to Accelerate Commercialization of ZELSUVMI
Ligand Pharmaceuticals Announces Launch of Pelthos Therapeutics to Accelerate Commercialization of ZELSUVMI™
Ligand Pharmaceuticals Appoints Scott Plesha to the Role of Chief Executive Officer
Ligand Pharmaceuticals Announces Launch of Pelthos Therapeutics
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A1C9RN Aktie
  4. Nachrichten Ligand Pharmaceuticals Incorporated
  5. Andere Sprachen